Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技(武漢)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

VOLUNTARY ANNOUNCEMENT

HANX BIOPHARMACEUTICALS PRESENTED FOUR POSTER PRESENTATIONS AT THE 2026 AACR MEETING

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the "**Company**" or "**Hanx Biopharmaceuticals**") on a voluntary basis.

The Board is pleased to announce that four innovative drug research abstracts of the Company have been presented in the form of posters at the 2026 Annual Meeting of the American Association for Cancer Research ("**AACR**"), held at the San Diego Convention Center, California, the United States from April 17 to 22, 2026. These selected achievements further validate the Company's research and development capabilities and innovation strength.

Details of the poster presentations are set out below:

1. CTLA-4/SIRPα BIFUNCTIONAL FUSION PROTEIN: HX044

HX044 is a globally innovative CTLA-4/SIRPα bifunctional fusion protein and a next-generation CTLA-4 targeted therapy. By simultaneously targeting CTLA-4 and CD47, it enhances the depletion of regulatory T-cells in the tumor microenvironment, thereby reducing tumor immunosuppression and strengthening anti-tumor activity. It is mainly developed for solid tumors resistant to PD-1/ICI therapy, forming a synergistic and complementary tumor immunology pipeline with HX009 developed by the Company.

- **Abstract Title:** Non-Clinical PK and PD Modeling to Assess the Therapeutic Window of HX044, a Novel CTLA4 x CD47 BsAb, as Comparison with Ipilimumab

- **Summary & Conclusions:**

    1. Different human tumors indeed have higher %CD47 + /CTLA4 + Treg than peripheral, and these TIL-Treg cells have higher levels of CTLA41, enabling preferential targeting of TIL-Treg by HX044 (vs Ipi).

    2. Considering increased efficacy by lowering efficacious dose levels, and minimal change in irAE dose levels (vs. Ipi), HX044 exhibited widened TW (could be around 4x).

These positive preclinical data have laid a solid foundation for the clinical development of HX044, which is currently in Phase I clinical stage.

2. BISPECIFIC ANTIBODY-DRUG CONJUGATE ("BsAb ADC"): HX116

HX116 is a potential first-in-class bispecific antibody-drug conjugate ("**BsAb ADC**") independently developed by the Company, targeting PD-(L)1 × VEGF. It incorporates additional mechanisms of action (such as direct tumor killing and anti-tumor immunity enhanced by immunogenic cell death) to boost anti-tumor activity and has significant market potential. In preclinical studies, HX116 demonstrated superior activity over its parental BsAb.

- **Abstract Title:** Explore a Novel Multi-Modal PD-L1xVEGF-ADCs (HX116) for Potential Enhanced Potency For Solid Tumor Treatments

- **Summary & Conclusions:**

    1. HX116 binds and internalizes to PD-L1 + cells, which are both enhanced in the presence of VEGF (abundant in tumors).

    2. HX116 internalizes efficiently into PD-L1 + tumor organoids and induced comparable cytotoxicity as SGN-PDL1V, the lead PD-L1-ADC in clinics; This observation may hint more specific targeting tumor (3D tumor organoid vs. 2D cells) or less off-tumor toxicity than SGN-PDL1V.

    3. All modalities of HX116 contributed to anti-tumor activity, superior to parental BsAb.

3. PD-L1 TARGETED ANTIBODY-DRUG CONJUGATE: HX112

HX112 is a novel PD-L1 targeted antibody-drug conjugate ("**ADC**") independently developed by the Company, intended for the treatment of pan-solid tumors.

- **Abstract Title:** A Novel Multi-Modal PD-L1-ADC Could be a Potential Candidate Treatment for Pan-Solid Tumors with Enhanced Tumor-Specificity

- **Summary & Conclusions:**

    1. Efficient internalization in 3D tumor organoids: In 2D cells, most PD-L1 ADCs show weak endocytosis and cytotoxicity, with the exception of SGN-PDL1V. In 3D organoids, HX112 exhibits internalization capacity and cytotoxicity comparable to SGN-PDL1V. Given that 3D tumor organoids more closely resemble the actual tumor phenotype, HX112 may have greater tumor specificity than SGN-PDL1V.

    2. Potential to avoid TME-cleavable linker design and reduce off-target toxicity: If HX112 can be efficiently internalized into tumor cells, it may not require a tumor microenvironment (TME)-cleavable linker, thereby avoiding the potential side effects associated with such a mechanism.

4. 3D TUMOR ORGANOID ADC EVALUATION SYSTEM

This study introduces an innovative preclinical ADC evaluation platform established by the Company, validating that 3D tumor organoids are more predictive of in vivo anti-tumor efficacy than 2D cell cultures.

- **Abstract Title:** 3D-Tumor Organoid, over 2D-Cell, Is More Predictive of In Vivo Anti-Cancer Pharmacology in Assessing ADC Candidates

- **Summary & Conclusions:**

    1. Despite similar high-affinity binding to PD-L1 or PD-L1+ 2D cell lines, antibodies targeting different epitopes, exhibited great differences in internalization, which may result in significant difference for the corresponding ADCs in cytotoxicity.

    2. 3D-tumor organoid are more predictive of in vivo anti-tumor pharmacology over 2D-cell cultures, supporting a more powerful streamlined assessment of preclinical ADC candidates using tumor organoid, in addition to 2D cell cultures.

The Company will continue to advance the research and development of its innovative drug pipeline, committed to providing more effective and safer treatment options for cancer patients.

ABOUT HANX BIOPHARMACEUTICALS

Established in 2014, HanX Biopharmaceuticals (Wuhan) Co., Ltd. is an innovative biotechnology company dedicated to structural biology, translational medicine, and clinical development. The company strives to develop next-generation immunotherapies to provide global patients with affordable, safe, and effective medical solutions, addressing the challenges of major diseases. Guided by a mission and vision driven by innovation, HanX Biopharmaceuticals focuses on discovering, developing, and commercializing First-in-Class and Best-in-Class therapies for cancer and autoimmune diseases. The company is committed to meeting unmet medical needs worldwide, advancing disease prevention, control, and ultimately elimination, and contributing to global health initiatives.

Warning under 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The relevant products may not ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing the Company's shares.

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, 24 April 2026

As at the date of this announcement, the Company's Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li, Ms. Xiao Jieyu and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian as a non-executive Director; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.